ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Albumin-Bound Paclitaxel

Also written as “ABI-007”, “nab-paclitaxel” and “Nab-paclitaxel”.

Its studies are mostly in Pancreatic Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Melanoma, led by 11 companies.

Drug pageAlbumin-Bound Paclitaxel: every studyMany companies study it; this page follows only the 51 they lead. All 527 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 28, 201451 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb380 open or runningphase 4since May 28, 2014Sep 30, 2002none ahead
CSPC Pharmaceutical Groupits history only31 open or runningphase 3since Aug 15, 2017Aug 15, 2017none ahead
Theriva Biologics SLits history only20 open or runningphase 1since Jan 21, 2014Jan 21, 2014none ahead
Academic Thoracic Oncology Medical Investigators Consortiumits history only10 open or runningphase 2since Mar 24, 2016Mar 24, 2016none ahead
Astellas Pharmaits history only10 open or runningphase 1since Nov 6, 2009Nov 6, 2009none ahead
EBG MedAustronits history only11 open or runningno phasesince May 10, 2021May 10, 2021Dec 31, 2026NCT04894643
Lee's Pharmaceuticalits history only10 open or runningphase 1since Sep 8, 2020Sep 8, 2020none ahead
Novartisits history only10 open or runningphase 2since Jul 1, 2008Jul 1, 2008none ahead
NovoCureits history only10 open or runningphase 2since Feb 29, 2024Feb 29, 2024none ahead
Otsukaits history only10 open or runningphase 2since Apr 16, 2008Apr 16, 2008none ahead

Also a collaborator on its studies: Gilead Sciences, Pfizer, Criterium and Shanghai Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 23 studies since Sep 30, 2002.

  1. Aug 28, 2013Phase 2 study in MelanomaNCT01933061
  2. Sep 27, 2013Phase 2 study in NeuroblastomaNCT01962103 · 107 enrolled · United States, Canada, France and more
  3. Oct 14, 2013Phase 3 study in Pancreatic NeoplasmsNCT01964430 · 866 enrolled · United States, Australia, Austria and more
  4. Dec 5, 2013Phase 2 study in Pancreatic NeoplasmsNCT02017015 · 83 enrolled · China
  5. Jan 2, 2014Phase 3 study in Carcinoma, Squamous CellNCT02027428 · 427 enrolled · United States, Germany, Italy and more
  6. Mar 31, 2014Phase 2 study in Colorectal NeoplasmsNCT02103062 · 41 enrolled · France
  7. May 28, 2014Phase 4 study in Carcinoma, Non-Small-Cell LungNCT02151149 · 143 enrolled · United States
  8. Sep 24, 2014Phase 2 study in Carcinoma, Non-Small-Cell LungNCT02250326 · 240 enrolled · United States, Canada, France and more
  9. Oct 1, 2014Phase 1 study in Pancreatic NeoplasmsNCT02267707 · 1 enrolled · United States, Germany
  10. Nov 10, 20142 phase 2 studiesNCT02289456, NCT02301143
  11. Dec 3, 2014Phase 1 study in Breast NeoplasmsNCT02309177 · 114 enrolled · United States
  12. Nov 30, 2015Phase 1 study in Pancreatic NeoplasmsNCT02620800 · 12 enrolled · United States
  13. Jun 9, 2017Phase 2 study in Colorectal NeoplasmsNCT03184870 · 332 enrolled · United States, Australia, Belgium and more
  14. Nov 6, 2017Phase 2 study in Advanced Pancreatic CancerNCT03336216 · 205 enrolled · United States, Canada, Denmark and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 38 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03336216Advanced Pancreatic Cancer · United States, Canada, Denmark and more2CompletedJun 1, 2023205
NCT03184870Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedApr 6, 2023332
NCT02620800Pancreatic Neoplasms · United States1CompletedOct 29, 201812
NCT02309177Breast Neoplasms · United States1CompletedSep 12, 2018114
NCT02301143Pancreatic Neoplasms · United States, Canada, France and more2CompletedNov 21, 2017107
NCT02289456Carcinoma, Non-Small-Cell Lung · United States2CompletedFeb 22, 201740
NCT02267707Pancreatic Neoplasms · United States, Germany1TerminatedFeb 10, 20161
NCT02250326Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2CompletedJul 17, 2017240
NCT02151149Carcinoma, Non-Small-Cell Lung · United States4CompletedJul 14, 2017143
NCT02103062Colorectal Neoplasms · France2CompletedNov 10, 201441
NCT02027428Carcinoma, Squamous Cell · United States, Germany, Italy and more3CompletedSep 15, 2017427
NCT02017015Pancreatic Neoplasms · China2CompletedJun 1, 201583
NCT01964430Pancreatic Neoplasms · United States, Australia, Austria and more3CompletedJun 30, 2022866
NCT01962103Neuroblastoma · United States, Canada, France and more2CompletedDec 5, 2017107
NCT01933061Melanoma2WithdrawnJan 20140
NCT01881230Breast Neoplasms · United States, Australia, Austria and more3CompletedOct 28, 2016191
NCT00864253Melanoma · United States, Australia, Canada and more3CompletedJun 1, 2012529
NCT00844649Pancreatic Neoplasms · United States, Australia, Austria and more3CompletedSep 17, 2012861
NCT00540514Carcinoma, Non-Small-Cell Lung · United States, Canada3CompletedOct 1, 20091,052
NCT00518284Peripheral Vascular Diseases · United States2TerminatedAug 20096
NCT00456846Breast Neoplasms · Canada2TerminatedDec 11, 2012123
NCT00407407Fallopian Tube Neoplasms · United States1TerminatedFeb 1, 20086
NCT00398086Pancreatic Neoplasms · United States2CompletedSep 1, 200867
NCT00394251Breast Neoplasms · United States2CompletedMar 1, 2007197
NCT00394082Breast Neoplasms · United States2CompletedSep 1, 200950
NCT00281528Breast Neoplasms · United States, Puerto Rico2TerminatedJul 1, 2010208
NCT00274456Breast Neoplasms · Ukraine2CompletedMar 1, 2008302
NCT00274443Carcinoma, Non-Small-Cell Lung · Russian Federation2CompletedJun 1, 2007250
NCT00249002Hemodialysis Graft Dysfunction · United States2TerminatedNov 1, 20079
NCT00140140Neoplasm Metastasis · United States2TerminatedFeb 200816
NCT00124943Coronary Restenosis2CompletedAug 2009112
NCT00107094Breast Neoplasms · United States1Completed30
NCT00093145Breast Neoplasms · United States2CompletedOct 1, 200832
NCT00093119Melanoma · United States2CompletedFeb 200575
NCT00073723Carcinoma, Non-Small-Cell Lung · United States2Completed75
NCT00046527Breast Neoplasms · United States3Completed460
NCT00046514Breast Neoplasms · United States2Completed100
NCT00046423Neoplasms · United States1Completed20

How it is read

Names in the registry

  • “ABI-007”, 15 entries
  • “nab-paclitaxel”, 13 entries
  • “Nab-paclitaxel”, 12 entries
  • “Nab-Paclitaxel”, 9 entries
  • “nab-Paclitaxel”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.